Key result
Intravenous enalaprilat during cardiopulmonary bypass caused dose-dependent reductions in mean arterial pressure (up to -36 mm Hg) and venous reservoir volume (up to -520 ml) compared to placebo.
Why the study?
Does intravenous enalaprilat alter arterial resistance and venous capacitance in male patients undergoing cardiopulmonary bypass?
Population
30 male patients undergoing cardiopulmonary bypass (CPB)
Comparison
Enalaprilat 0.04 mg/kg or 0.08 mg/kg given as an… vs Saline solution as placebo given as an…
Design
RCT, randomized sequence
Follow-up
acute (during CPB)
Authors
Loading...
Requires close hemodynamic monitoring to avoid hypotension during bypass; confirms dose-dependent arterial and venous vasodilation in this setting.
RCT (n=30)
Randomized sequence
Does intravenous enalaprilat alter arterial resistance and venous capacitance in male patients undergoing cardiopulmonary bypass?
Intravenous enalaprilat produces dose-dependent arterial and venous vasodilation, reducing pre- and afterload during cardiopulmonary bypass.
Boldt et al. (1994) conducted an RCT in Undergoing cardiopulmonary bypass (CPB) (n=30). Enalaprilat vs. Saline solution (placebo) was evaluated on Changes in mean arterial pressure (MAP) and venous reservoir (RV). Intravenous enalaprilat during cardiopulmonary bypass caused dose-dependent reductions in mean arterial pressure (up to -36 mm Hg) and venous reservoir volume (up to -520 ml) compared to placebo.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: